Table Info

Table 1.

Summary of broad treatment options with general indications and limitations

Intervention	Indication	Limitations
Surgical resection	Single lesion resection and symptom relief	Multiple disseminated lesions
Whole-brain radiotherapy	High metastatic tumor load (> 10 metastases)	Off-target radiation with neurological decline
Stereotactic radiosurgery	Lesion diameters < 3 cm	High metastatic tumor load (> 10 metastases)
Systemic therapy	Therapeutic targets present	Lack of therapeutic targets

Declarations

Author contributions

MW and JW contributed to writing and editing. BLW contributed to conceptualization, writing, editing, and study oversight.

Conflicts of interest

The author declares that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

U.S. cancer statistics breast cancer stat bite [Internet]. Atlanta (GA): Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2021 [cited 2022 Feb 8]. Available from: https://www.cdc.gov/cancer/uscs/about/stat-bites/stat-bite-breast.htm

Cancer stat facts: female breast cancer [Internet]. Atlanta (GA): National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services; 2021 [cited 2022 Mar 4]. Available from: https://seer.cancer.gov/statfacts/html/breast.html

Breast cancer now most common form of cancer: WHO taking action [Internet]. Geneva (CH): World Health Organization; 2021 [cited 2021 Feb 8]. Available from: https://www.who.int/news/item/03-02-2021-breast-cancer-now-most-common-form-of-cancer-who-taking-action

Bailey ST, Shin H, Westerling T, Liu XS, Brown M. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci U S A. 2012;109:18060–5. [DOI] [PubMed] [PMC]

Lei JT, Anurag M, Haricharan S, Gou X, Ellis MJ. Endocrine therapy resistance: new insights. Breast. 2019;48 Suppl 1:S26–30. [DOI] [PubMed] [PMC]

Hartkopf AD, Grischke EM, Brucker SY. Endocrine-resistant breast cancer: mechanisms and treatment. Breast Care (Basel). 2020;15:347–54. [DOI] [PubMed] [PMC]

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48. [DOI] [PubMed]

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC4)^†. Ann Oncol. 2018;29:1634–57. [DOI] [PubMed] [PMC]

Cacho-Díaz B, Spínola-Maroño H, Arrieta VA, Granados-García M, Wegman-Ostrosky T, Mendoza-Olivas LG, et al. Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms. Clin Neurol Neurosurg. 2018;173:61–4. [DOI] [PubMed]

10.

Leone JP, Leone BA. Breast cancer brain metastases: the last frontier. Exp Hematol Oncol. 2015;4:33. [DOI] [PubMed] [PMC]

11.

Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, et al. Brain metastases. Nat Rev Dis Primers. 2019;5:5. [DOI] [PubMed]

12.

Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2010;16:116–22. [DOI] [PubMed]

13.

Heyn C, Ronald JA, Ramadan SS, Snir JA, Barry AM, MacKenzie LT, et al. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med. 2006;56:1001–10. [DOI] [PubMed]

14.

Wrobel JK, Toborek M. Blood-brain barrier remodeling during brain metastasis formation. Mol Med. 2016;22:32–40. [DOI] [PubMed] [PMC]

15.

Ni W, Chen W, Lu Y. Emerging findings into molecular mechanism of brain metastasis. Cancer Med. 2018;7:3820–33. [DOI] [PubMed] [PMC]

16.

Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23:85. [DOI] [PubMed] [PMC]

17.

Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun. 2016;7:11579. [DOI] [PubMed] [PMC]

18.

Zundelevich A, Dadiani M, Kahana-Edwin S, Itay A, Sella T, Gadot M, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020;22:16. [DOI] [PubMed] [PMC]

19.

Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol. 2021;12:628690. [DOI] [PubMed] [PMC]

20.

Safa AR. Chapter 7-Cancer stem cells, apoptosis pathways and mechanisms of death resistance. In: Dammacco F, Silvestris F, editors. Oncogenomics. Academic Press; 2019. pp. 89–101. [DOI]

21.

Siersbæk R, Kumar S, Carroll JS. Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancer. Genes Dev. 2018;32:1141–54. [DOI] [PubMed] [PMC]

22.

Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11:797. [DOI] [PubMed] [PMC]

23.

Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64. [DOI] [PubMed] [PMC]

24.

Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51. [DOI] [PubMed] [PMC]

25.

Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci. 2020;22:173. [DOI] [PubMed] [PMC]

26.

Dore-Savard L, Lee E, Kakkad S, Popel AS, Bhujwalla ZM. The angiogenic secretome in VEGF overexpressing breast cancer xenografts. Sci Rep. 2016;6:39460. [DOI] [PubMed] [PMC]

27.

Ippen FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, et al. The dual PI3K/mTOR pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases. Clin Cancer Res. 2019;25:3374–83. [DOI] [PubMed] [PMC]

28.

Laoukili J, Kooistra MR, Brás A, Kauw J, Kerkhoven RM, Morrison A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 2005;7:126–36. [DOI] [PubMed]

29.

Leung TW, Lin SS, Tsang AC, Tong CS, Ching JC, Leung WY, et al. Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett. 2001;507:59–66. [DOI] [PubMed]

30.

Hamurcu Z, Ashour A, Kahraman N, Ozpolat B. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. Oncotarget. 2016;7:16619–35. [DOI] [PubMed] [PMC]

31.

Wu QF, Liu C, Tai MH, Liu D, Lei L, Wang RT, et al. Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro. Acta Pharmacol Sin. 2010;31:361–6. [DOI] [PubMed] [PMC]

32.

Yan J, Hou J, Yan Y, Ren XY, Luo HN, Wang ZG, et al. Knockdown of FOXM1 suppresses cell growth and metastasis in human laryngeal cancer via the AKT signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24:6786–93. [DOI] [PubMed]

33.

Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res. 2010;8:24–34. [DOI] [PubMed] [PMC]

34.

Millour J, Constantinidou D, Stavropoulou AV, Wilson MS, Myatt SS, Kwok JM, et al. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene. 2010;29:2983–95. [DOI] [PubMed] [PMC]

35.

Zhang YL, Ma Y, Zeng YQ, Liu Y, He EP, Liu YT, et al. A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics. Ann Transl Med. 2021;9:1704. [DOI] [PubMed] [PMC]

36.

Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, et al. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol. 2009;35:57–68. [DOI] [PubMed] [PMC]

37.

Wang Y, Tzeng YT, Chang G, Wang X, Chen S. Amphiregulin retains ERα expression in acquired aromatase inhibitor resistant breast cancer cells. Endocr Relat Cancer. 2020;27:671–83. [DOI] [PubMed] [PMC]

38.

Pham TH, Page YL, Percevault F, Ferrière F, Flouriot G, Pakdel F. Apigenin, a partial antagonist of the estrogen receptor (ER), inhibits ER-positive breast cancer cell proliferation through Akt/FOXM1 signaling. Int J Mol Sci. 2021;22:470. [DOI] [PubMed] [PMC]

39.

Niu Y, Xu J, Sun T. Cyclin-dependent kinases 4/6 inhibitors in breast cancer: current status, resistance, and combination strategies. J Cancer. 2019;10:5504–17. [DOI] [PubMed] [PMC]

40.

Scheidemann ER, Shajahan-Haq AN. Resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer. Int J Mol Sci. 2021;22:12292. [DOI] [PubMed] [PMC]

41.

Alves CL, Ehmsen S, Terp MG, Portman N, Tuttolomondo M, Gammelgaard OL, et al. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. Nat Commun. 2021;12:5112. [DOI] [PubMed] [PMC]

42.

Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19:1997–2007. [DOI] [PubMed] [PMC]

43.

Dischinger PS, Tovar EA, Essenburg CJ, Madaj ZB, Gardner EE, Callaghan ME, et al. NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer. NPJ Breast Cancer. 2018;4:29. [DOI] [PubMed] [PMC]

44.

Sokol ES, Feng YX, Jin DX, Basudan A, Lee AV, Atkinson JM, et al. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. Ann Oncol. 2019;30:115–23. [DOI] [PubMed] [PMC]

45.

Huang RSP, Haberberger J, McGregor K, Mata DA, Decker B, Hiemenz MC, et al. Clinicopathologic and genomic landscape of breast carcinoma brain metastases. Oncologist. 2021;26:835–44. [DOI] [PubMed] [PMC]

46.

Giuliano M, Trivedi MV, Schiff R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care (Basel). 2013;8:256–62. [DOI] [PubMed] [PMC]

47.

Kwon YS, Nam KS, Kim S. Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway. Biochem Pharmacol. 2021;190:114635. [DOI] [PubMed]

48.

Kavarthapu R, Anbazhagan R, Dufau ML. Crosstalk between PRLR and EGFR/HER2 signaling pathways in breast cancer. Cancers (Basel). 2021;13:4685. [DOI] [PubMed] [PMC]

49.

Hatiboglu MA, Wildrick DM, Sawaya R. The role of surgical resection in patients with brain metastases. Ecancermedicalscience. 2013;7:308. [DOI] [PubMed] [PMC]

50.

Nahed BV, Alvarez-Breckenridge C, Brastianos PK, Shih H, Sloan A, Ammirati M, et al. Congress of neurological surgeons systematic review and evidence-based guidelines on the role of surgery in the management of adults with metastatic brain tumors. Neurosurgery. 2019;84:E152–5. [DOI] [PubMed]

51.

Paek SH, Audu PB, Sperling MR, Cho J, Andrews DW. Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery. 2005;56:1021–34. [PubMed]

52.

Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134–41. [DOI] [PubMed] [PMC]

53.

Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485–9. [DOI] [PubMed]

54.

July J, Pranata R. Hypofractionated versus single-fraction stereotactic radiosurgery for the treatment of brain metastases: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2021;206:106645. [DOI] [PubMed]

55.

Koo T, Kim K, Park HJ, Han SW, Kim TY, Jeong SY, et al. Prognostic factors for survival in colorectal cancer patients with brain metastases undergoing whole brain radiotherapy: multicenter retrospective study. Sci Rep. 2020;10:4340. [DOI] [PubMed] [PMC]

56.

Akanda ZZ, Hong W, Nahavandi S, Haghighi N, Phillips C, Kok DL. Post-operative stereotactic radiosurgery following excision of brain metastases: a systematic review and meta-analysis. Radiother Oncol. 2020;142:27–35. [DOI] [PubMed]

57.

Krishnan M, Krishnamurthy J, Shonka N. Targeting the sanctuary site: options when breast cancer metastasizes to the brain. Oncology (Williston Park). 2019;33:683730. [PubMed]

58.

Bachmann N, Leiser D, Ermis E, Vulcu S, Schucht P, Raabe A, et al. Impact of regular magnetic resonance imaging follow-up after stereotactic radiotherapy to the surgical cavity in patients with one to three brain metastases. Radiat Oncol. 2019;14:45. [DOI] [PubMed] [PMC]

59.

Rani A, Stebbing J, Giamas G, Murphy J. Endocrine resistance in hormone receptor positive breast cancer-from mechanism to therapy. Front Endocrinol (Lausanne). 2019;10:245. [DOI] [PubMed] [PMC]

60.

Bergen ES, Binter A, Starzer AM, Heller G, Kiesel B, Tendl-Schulz K, et al. Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab. Ther Adv Med Oncol. 2021;13:17588359211009002. [DOI] [PubMed] [PMC]

61.

Nader-Marta G, Martins-Branco D, de Azambuja E. How we treat patients with metastatic HER2-positive breast cancer. ESMO Open. 2022;7:100343. [DOI] [PubMed] [PMC]

62.

Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25:1116–21. [DOI] [PubMed] [PMC]

63.

Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. LBA1 trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Ann Oncol. 2021;32:S1287–8. [DOI]

64.

Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38:2610–19. [DOI] [PubMed] [PMC]

65.

Shah M, Wedam S, Cheng J, Fiero MH, Xia H, Li F, et al. FDA approval summary: tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021;27:1220–26. [DOI] [PubMed]

66.

Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2- directed regimens: phase III NALA trial. J Clin Oncol. 2020;38:3138–49. [DOI] [PubMed] [PMC]

67.

Specchia ML, Frisicale EM, Carini E, Di Pilla A, Cappa D, Barbara A, et al. The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res. 2020;20:73. [DOI] [PubMed] [PMC]

68.

Larson KL, Huang B, Weiss HL, Hull P, Westgate PM, Miller RW, et al. Clinical outcomes of molecular tumor boards: a systematic review. JCO Precis Oncol. 2021;5:1122–32. [DOI] [PubMed] [PMC]

69.

Wang N, Cohen JV, Goss NC, Bertalan M, Keeley MC, Cahill DP, et al. The impact of a dedicated multidisciplinary tumor board on care for patients with brain metastases. J Clin Oncol. 2019;37:e13585. [DOI]

70.

Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16:5664–78. [DOI] [PubMed] [PMC]

71.

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al.; ASCENT Clinical Trial Investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–41. [DOI]

72.

Kharouta M, Zender C, Podder T, Rezaee R, Lavertu P, Fowler N, et al. Permanent interstitial cesium-131 brachytherapy in treating high-risk recurrent head and neck cancer: a prospective pilot study. Front Oncol. 2021;11:639480. [DOI] [PubMed] [PMC]

73.

Watase C, Shiino S, Shimoi T, Noguchi E, Kaneda T, Yamamoto Y, et al. Breast cancer brain metastasi-overview of disease state, treatment options and future perspectives. Cancers (Basel). 2021;13:1078. [DOI] [PubMed] [PMC]

74.

Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727–42. [PubMed] [PMC]

75.

Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al.; PALOMA3 Study Group. Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med. 2015;373:209–19. [DOI] [PubMed]

76.

Barroso-Sousa R, Shapiro GI, Tolaney SM. Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer. Breast Care (Basel). 2016;11:167–73. [DOI] [PubMed] [PMC]

77.

Bailleux C, Eberst L, Bachelot T. Treatment strategies for breast cancer brain metastases. Br J Cancer. 2021;124:142–55. [DOI] [PubMed] [PMC]

78.

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6:740–53. [DOI] [PubMed]

79.

Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, et al. A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res. 2020;26:5310–19. [DOI] [PubMed]

80.

Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, et al. First-in-human phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma. Clin Cancer Res. 2020;26:1820–28. [DOI] [PubMed]

81.

Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018;24:1024–35. [DOI] [PubMed]

82.

Ren D, Cheng H, Wang X, Vishnoi M, Teh BS, Rostomily R, et al. Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience. Ther Adv Med Oncol. 2020;12:1–11. [DOI] [PubMed] [PMC]